Related Experiment Video
Updated: Oct 16, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
A Phenotypic Screen Identifies a Compound Series That Induces Differentiation of Acute Myeloid Leukemia Cells In
Laia Josa-Culleré1, Katrina S Madden1, Thomas J Cogswell2
1Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K.
Abstract:
Induction of differentiation is a promising therapeutic strategy against acute myeloid leukemia. However, current differentiation therapies are effective only to specific patient populations. To identify novel differentiation agents with wider efficacy, we developed a phenotypic high-throughput screen with a range of genetically diverse cell lines. From the resulting hits, one chemical scaffold was optimized in terms of activity and physicochemical properties to yield OXS007417, a proof-of-concept tool compound, which was also able to decrease tumor volume in a murine in vivo xenograft model.
Insights
Researchers identified a new compound, OXS007417, that effectively induces cell differentiation to treat acute myeloid leukemia (AML). This novel agent shows promise for broader patient populations and reduced tumor growth in preclinical models.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Inducing cell differentiation is a key therapeutic strategy for acute myeloid leukemia (AML).
- Current differentiation therapies exhibit limited efficacy in specific patient subsets.
- There is a need for novel differentiation agents with broader applicability.
Purpose of the Study:
- To discover novel chemical compounds that induce cell differentiation in AML.
- To identify a potent differentiation agent with improved efficacy and physicochemical properties.
- To evaluate the therapeutic potential of a lead compound in preclinical AML models.
Main Methods:
- A phenotypic high-throughput screening assay was employed using a diverse panel of AML cell lines.
- Hit compounds were identified and a specific chemical scaffold was optimized.
- The lead compound, OXS007417, was characterized for activity and physicochemical properties.
- Efficacy of OXS007417 was assessed in a murine xenograft model of AML.
Main Results:
- A novel chemical scaffold was identified through high-throughput screening.
- Optimization yielded OXS007417, a potent inducer of cell differentiation.
- OXS007417 demonstrated favorable activity and physicochemical characteristics.
- The compound significantly reduced tumor volume in a preclinical AML xenograft model.
Conclusions:
- OXS007417 is a promising proof-of-concept tool compound for AML differentiation therapy.
- The identified agent has potential for wider efficacy compared to existing therapies.
- Further investigation of OXS007417 warrants its development as a therapeutic candidate for AML.
Related Concept Videos
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...